Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Viracept

Known as: Agouron Brand of Nelfinavir Mesylate, Roche Brand of Nelfinavir Mesylate 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2020
Highly Cited
2020
Severe acute respiratory syndrome coronavirus‐2 (SARS CoV‐2) is the causative agent of the coronavirus disease‐2019 (COVID‐19… Expand
Review
2009
Review
2009
Based on a production accident Viracept (nelfinavir mesilate) tablets, an HIV protease inhibitor supplied by Roche outside the US… Expand
2009
2009
Viracept (nelfinavir) is an HIV protease inhibitor supplied by Roche outside the US, Canada and Japan. Viracept was first… Expand
  • table 1
Review
2009
Review
2009
A technical review of the events leading to the global recall of Viracept film coated tablets 250 mg in June 2007 is given from… Expand
  • figure 1
  • figure 2
  • figure 3
  • table 1
  • figure 4
2009
2009
This perspective first considers the potential impact of the Viracept-EMS case in the framework of the current understanding of… Expand
Review
2009
Review
2009
Roche's protease inhibitor nelfinavir mesylate (Viracept®) produced between March 2007-June 2007 was found to contain elevated… Expand
2002
2002
Summary Forty (40) HIV positive patients with CD4 cell counts between 100 - 500 cellh/mm3 were recruited from 8 different centres… Expand
Highly Cited
2001
Highly Cited
2001
  • Kanyin E. Zhang, E. Wu, +7 authors S. Webber
  • Antimicrobial Agents and Chemotherapy
  • 2001
  • Corpus ID: 44534215
ABSTRACT Nelfinavir mesylate (Viracept, formally AG1343) is a potent and orally bioavailable human immunodeficiency virus (HIV… Expand
Highly Cited
1999
Highly Cited
1999
A 32-year-old African American woman with human immunodeficiency virus 1 (HIV-1) and a 3-year history of extensive facial… Expand
  • figure 1
  • figure 2
Highly Cited
1997
Highly Cited
1997
Using a combination of iterative structure-based design and an analysis of oral pharmacokinetics and antiviral activity, AG1343… Expand